Gerd R. Burmester, ACR 2021: Long-term Sarilumab Treatment for Active Rheumatoid Arthritis
We were delighted to speak with Professor Gerd R. Burmester (Charité – Universitätsmedizin Berlin, Berlin, Germany) around the open label extension studies of sarilumab for the treatment of active rheumatoid arthritis (EXTEND: NCT01146652 and MONARCH: NCT02332590).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Safety and Efficacy of Long-term Sarilumab Treatment in Patients with Active Rheumatoid Arthritis: EXTEND and MONARCH Open Label Extension Studies.‘ (ABSTRACT NUMBER: 1690) was presented at the ACR Convergence, 3-9 November 2021.
Questions
- In which patients with rheumatoid arthritis (RA) is sarilumab indicated? (0:15)
- What were the aims and design of the analysis of the EXTEND and MONARCH studies? (0:41)
- What were the efficacy and safety findings of this analysis? (1:41)
- How did these findings compare with other studies? (2:48)
- What can we conclude about the long-term efficacy and safety of sarilumab in RA and what questions remain unanswered? (3:20)
Disclosures: Gerd R. Burmester discloses honoraria for lectures and consulting for Sanofi and Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
